Fig. 7.

MiR-125b directly targeted Sirt7. A Predicted binding sites between miR-125b and the Sirt7 3’-UTR. B Dual-luciferase assays were performed in fibroblasts after co-transfection with SIRT7 3’-UTR wild-type (WT) or mutant (MUT) plasmids, and miR-125b mimics or miR-NC mimic. ^*P < 0.05 versus miR-125b mimic in repeated measures analysis of variance (n = 6) in the WT group. C QRT-PCR for Sirt7 treated with RNA pull down assay. ^*P < 0.05 versus Control probe in paired t-test (n = 3). D, E Western blot was used to analyze protein level of fibroblasts treated with miR-125b mimic, miR-NC mimic, miR-125b inhibitor, miR-NC inhibitor respectively. ^*P < 0.05 versus miR-NC mimic; ^#P < 0.05 versus miR-NC inhibitor in paired t-test (n = 3). F, G Western blot analysis of Sirt7 and β-actin protein levels in fibroblast^Old treated with exosome^Young, exosome^{Young+miR−125b inhibitor} or exosome^{Young+miR−NC inhibitor}. Untreated fibroblast^Old were used as control. ^*P < 0.05 versus Control; ^#P < 0.05 versus exosomes^{Young+miR−125b inhibitor} in repeated measures analysis of variance (n = 6)